Avalanche Biotechnologies Falls Upon Ditching Eye Trial Plan

Updated on

Shares of Avalanche Biotechnologies Inc. plummeted to a record low after the company said it won’t move forward with a trial of its gene therapy for an eye disease this year.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.